CDEX Inc. Begins Trading Under New Stock Symbol

Published: Nov 19, 2012

TUCSON, AZ--(Marketwire - November 19, 2012) - CDEX Inc. (OTCQB: CEXID), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today announced the Company's common stock will begin trading under the new symbol "CDEX" (OTCQB: CDEX) effective the first day of trading November 19, 2012. The Company's share trading symbol change reflects the company's successful restructuring and more accurately identifies the company.

"This transition reflects the completion of the positive restructuring we completed," said Jeff Brumfield, chairman and chief executive officer of CDEX Inc. "We continue to see strong interest in our proprietary safety and detection products both domestically and internationally, we remain very optimistic of our future outlook."

About CDEX Inc.
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.